InSitu Biologics says it is looking for investors to support its hydrogel-based drug delivery system AnestaGel.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014.
Lonza has confirmed it is interested in buying Capsugel.
Biogen has licensed rights use a gene therapy delivery technology from developer Regenxbio.
Discovery services firm Selvita plans a new laboratory in Poland citing a desired to develop the facility as its “second heart.”
Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.
Patheon has sold a production plant in Italy to LIVIA and agreed to a management buyout at a site in Austria as it prepares to go public.
Indian CRO Syngene has received approval for its IPO prospectus paving the way to spin out from its parent company Biocon.
Biocorp has raised €8.9m ($9.8m) through an IPO during what it called a period of “deep macroeconomic uncertainty” and has underlined plans to grow its drug delivery tech business internationally.
In France’s largest ever biotech IPO, Abivax has raised €58m ($64m) to continue developing its HIV and Hep B candidates.
Delivery device maker Biocorp has announced plans to go public and list of Paris’ Alternext market as part of an effort to win more Big Pharma deals.
Indian CRO Syngene has reported a record quarter as it gets set to spin-out from its parent company Biocon.
Apax Partners says workers' unions have backed its plan to buy a controlling stake in chemical distributor Azelis from fellow private equity firm 3i.
Danish diabetes specialist Novo Nordisk plans to float its IT services business NNIT on the NASDAQ exchanged in Copenhagan.
Quintiles has been upgraded to stable by ratings agency Standard & Poor after a second stock offering and the consolidation of debt through a $300m securitisation facility.
The Raleigh, North Carolina-based CRO INC Research plans to raise about $150m in its initial public offering via about 8.1m shares at a price range of $17 to $20 per share.
Following pushes to go public by top peers, CRO INC Research has filed an S-1 with the SEC in preparation for an IPO (initial public offering) on the NASDAQ.
Newly public Horizon Discovery Group says it is looking for more acquisitions to become a fully integrated products, services and research provider as revenues soars 35%.
Experts have predicted more CROs will go public as Private Equity looks to get a return on its investments, but such shifts are indicative of a booming market rather than waning interest.
Recipharm AB will continue its spending spree of the past few years according to CEO Thomas Eldered, who reiterated the CMO’s plan to grow through takeovers in a results presentation earlier today.
Recipharm AB will manufacture commercial supplies of a topical formulation of the anaesthetic lidocaine called Shact that is soon to be launched by developer Pharmanest AB.
Dutch API and excipients distributor IMCD has increased the number of shares it will make available in its initial public offering (IPO), citing demand.
PRA Prepares to Go Public with Confidential SEC Filing
US CRO PRA is proposing to go public again, more than six years since it was taken private, according to a confidential draft registration statement submitted to the US SEC.
Quintiles and investor TPG Capital declined to comment on rumours the CRO is sizing up banks and preparing for an IPO.
A SEC filing has created speculation that Medidata is the target of a private equity takeover attempt by Vista Equity Partners.
A Chinese company that offers drug development services using a network of 99 third-party vendors has filed an $80m IPO.
Earnings at Catalent jumped in the second quarter as rising demand for its oral technologies offset weakness in sterile injectables.
Analysts back CMO Arch’s IPO on CRAMS biz potential
An expanding CRAMS business and bulk drug strength makes Indian CMO Arch Pharmalabs’ IPO a solid investment, analysts report.
Aanjaneya’s profit soars as post-IPO expansion continues
Net profit at Indian API and formulation business Aanjaneya Lifecare jumped as it enacted post-IPO expansion plans to ‘dominate’ its markets.
Private equity firm in talks to buy PPD in $4bn deal; reports
Carlyle Group is in exclusive talks to buy PPD in a deal valuing the CRO at around $4bn (€2.8bn), according to reports.
Private equity CRO buying spree set to continue
Private equity firms have snapped up CROs over the past year and, with a number of vendors said to be up for sale, the trend is set to continue.
ShangPharma eyes biologics, cGMP to build on ’10 growth
ShangPharma expects its cGMP production site, due to open in 2011, and biologics services to drive growth as it builds on a 17 per cent increase in revenues in the third quarter.
Possible IPO for GSK and Pfizer’s HIV company
The HIV company, ViiV, set up by GlaxoSmithKline and Pfizer in 2009, might be spun off and floated in an initial public offering.
Codexis plans $103m IPO this week
Biocatalysis specialist Codexis aims to raise $103m in another initial public offering (IPO) on the Nasdaq Global Market.
Appointments at Clearstone Central Laboratories, NexMed and RRD – People on the move
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Clearstone Central Laboratories, NexMed and RRD.
Medidata inks EDC deal with Roche
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
Media reports of a new CEO at Proctor & Gamble – People on the move
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including media reports of a new CEO at Proctor & Gamble.
Medidata plans $86m IPO
eClinical specialist Medidata Solutions has filed to list on the US Nasdaq exchange via an initial public offering that it hopes will raise $86m.
Start-ups shot down as credit crunches
The credit crunch is putting the squeeze on start-ups and
established companies alike, with numerous firms struggling to
obtain the financing that is their lifeblood.
CRAMS sector key to Anu's future
Indian contract drugmaker Anu's Laboratories will focus its efforts
on expanding its presence in the country's booming contract
research and manufacturing (CRAMS) market, according to managing
director Hari Babu.
Akela Pharma to sue LAB Research over tox studies
Akela Pharma has notified LAB Research of its intention to initiate
legal proceedings to recover the cost of preclinical
studies it ran in Hungary that were rejected by the US
Credit crunch sinks MonoSol IPO
A planned $60-$70m (€38-€44m) initial public offering (IPO) by
US-based drug delivery specialist MonoSol Rx has fallen foul of the
credit crunch and fears about a slowing US economy.
Gerresheimer going strong
German packaging firm Gerresheimer has reported healthy first half
financial results, boosted by a series of strategic acquisitions
and favourable market conditions, with the firm's recent initial
public offering promising to...
WuXi PharmaTech plans $120m US public offering
WuXi PharmaTech, the biggest Chinese contract research organisation
(CRO), has put an end to weeks of speculation by officially
announcing it plans an initial public offering (IPO) on the New
York Stock Exchange.
Vivascience IPO shelved once again
Germany's Sartorius has decided to call off the initial public
offering of Vivascience, which makes products for the analysis and
purification of proteins.
Biotech's Q3 fundraising brings total to $20 billion
The biotech industry managed to raise almost $6 billion during the
third quarter bringing the total raised this year to $20 billion
(€16.2 billion), an increase of $3.2 billion from this time last
year, reflecting the growing confidence...
Acrux aims to make €18m from IPO
Australian drug delivery company Acrux is hoping to raise A$30
million (€18m) in a float on the Australian Stock Exchange to
support the development of its novel transdermal technology that
does not require the use of adhesive patches...
Sartorius planning Vivascience IPO?
Sartorius, a German manufacturer of laboratory equipment, is
considering a possible initial public offering for its
biotechnology unit Vivascience in the second half of this year,
according to local press reports.
Lanxess achieves independence
Lanxess, the new company in which Germany's Bayer will combine
almost all areas of its chemicals business and parts of its
polymers activities, begins operating as an independent unit today.